Welcome to GALIBRA NEUROSCIENCE
Advancing gene therapy for GABA disorders
Our vision
Our mission is to lead innovation in gene therapy for GABA disorders.
We are committed to the translation of cutting-edge science to meet urgent patient needs.
We aim to empower lives and set new standards for excellence in personalized healthcare.
About Us
GALIBRA NEUROSCIENCE
Galibra Neuroscience was founded in 2023 by a clinician and a scientist at Boston Children’s Hospital affiliated with Harvard Medical School. Our founders have over 25 years of experience in clinical care and translational research. We are directing our knowledge to improve patient lives.
Our Science
GABA biology. A focused therapeutic strategy.
GABA (gamma-aminobutyric acid) is a major inhibitory neurotransmitter in the brain. Genetic changes affecting its metabolism or signalling can cause serious neurological disorders.
Galibra is pursuing gene-based approaches aimed at addressing the underlying biology of GABA disorders. Our research spans monogenic rare disorders and broader neurological conditions.
Our goal is to translate mechanistic insight into disease-modifying therapies. Each program requires rigorous preclinical and clinical evaluation to establish safety and efficacy.
Why GALIBRA?
We leverage strong partnerships with leading academic institutes and patient advocacy groups to streamline bench to bedside translation of novel disease-modifying therapies.
Pipeline
Leadership
Read biography →
Read biography →
Read biography →
Read biography →
Read biography →
Read biography →
